PALI — PALISADE BIO, INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1357459 ·
Last close
$2.01
Market Cap
$350.28M
52W High
$2.29
52W Low
$1.64
ADV30
1,972,880
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -10,748,000 | -9,600,000 | 133,315,000 | 132,628,000 | 5,953,000 |
| Dec 2025 | 0 | — | -9,981,000 | -8,899,000 | 134,344,000 | 133,385,000 | 4,964,000 |
| Sep 2025 | 0 | — | -2,922,000 | -2,868,000 | 6,973,000 | 5,227,000 | 3,761,000 |
| Jun 2025 | 0 | — | -2,843,000 | -2,784,000 | 6,667,000 | 5,417,000 | 4,047,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-12,404,000
Investing CF
$0
Financing CF
$137,831,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.48
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-162,325,000
Inventory
—
Receivables
$9,000
ST Investments
—
EBIT TTM
$-24,141,000
Pretax Income TTM
$-24,151,000
Interest Exp TTM
$10,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$500,000
EBITDA
$-35,346,500
Free Cash Flow
$-8,654,125
Enterprise Value
$240,798,176
Total Cash
$125,172,000
Total Debt
$0
Shares Out
174,270,558
Trailing EPS
$0.65
Book Value
$0.70
ROE
-51.4%
ROA
-33.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -18,056,000 | -16,781,000 | 134,344,000 | 4,964,000 | — | -10,847,000 |
| Dec 2024 | 0 | -14,859,000 | -14,438,000 | 10,880,000 | 3,388,000 | — | -12,193,000 |
| Dec 2023 | 250,000 | -12,845,000 | -12,300,000 | 14,052,000 | 2,739,000 | — | -11,133,000 |
| Dec 2022 | 0 | -15,311,000 | -14,260,000 | 15,763,000 | 3,284,000 | — | -13,360,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.28
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IKT | Inhibikase Therapeutics, Inc. | $348.84M | $2.50 | — |
| AGEN | AGENUS INC | $345.22M | $7.67 | — |
| STRO | SUTRO BIOPHARMA, INC. | $339.75M | $20.49 | — |
| PROK | PROKIDNEY CORP. | $336.37M | $1.61 | — |
| SABS | SAB Biotherapeutics, Inc. | $329.37M | $3.62 | — |
News headlines (Yahoo Finance, 1h cache)
Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2
2026-07-27 11:30 · Yahoo
PALI Stock Heads For Best Day In Seven Months – What’s Driving Today’s Rally?
2026-06-29 17:49 · Yahoo
Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors
2026-06-11 12:45 · Yahoo
Palisade Bio to Participate in the Jefferies Global Healthcare Conference
2026-05-27 13:00 · Yahoo
Palisade Bio (PALI) Reports Q1 2026 Results as R&D Expenses Rise to $6.4M
2026-05-18 04:49 · Yahoo
We're Not Worried About Palisade Bio's (NASDAQ:PALI) Cash Burn
2026-05-15 11:00 · Yahoo
Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
2026-05-12 20:15 · Yahoo
Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis
2026-05-05 12:30 · Yahoo
Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile
2026-04-17 13:57 · Yahoo
Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development
2026-08-10 20:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.